Hallux

Executive Summary

Hallux Inc. is a clinical-stage biopharmaceutical company developing a novel topical treatment for onychomycosis (fungal nail infection). Its lead candidate, Hallux Subungual Gel (HSG), is a physician-applied terbinafine formulation designed to directly target the infection site under the nail, offering a potential alternative to oral therapies with systemic side effects and low-efficacy topical options. Founded in 2018 and based in San Diego, the company is currently in Phase 2 clinical trials. If successful, HSG could address a significant unmet need in a large market, given that current treatments often require months of daily application or carry risks of liver toxicity and drug interactions. Hallux's approach aims to improve efficacy and convenience while maintaining a favorable safety profile.

Upcoming Catalysts (preview)

• H2 2026Phase 2 Top-Line Data Readout60% success
• 2027Strategic Partnership or Licensing Deal50% success
• Q4 2026FDA End-of-Phase 2 Meeting Feedback70% success